Results 11 to 20 of about 4,836 (184)

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials [PDF]

Rheumatology and Therapy
Introduction The ongoing KEEPsAKE 1 and 2 (KS1; KS2) trials evaluate the efficacy and safety of risankizumab in patients with psoriatic arthritis (PsA) who had an inadequate response to ≥ 1 conventional synthetic disease-modifying antirheumatic drug(s ...
Andrew Östör, Filip Van den Bosch, Kim Papp, Mauro Keiserman, Ricardo Blanco, Angela Crowley, Douglas White, Ana Biljan, Tshepiso Madihlaba, Kyle Carter, Fang Liu, Ahmed M. Soliman, Doug Ashley, Michael Chen, Lila Glotfelty, Alan Kivitz   +15 more
doaj   +2 more sources

Risankizumab: Mechanism of action, clinical and translational science

Clinical and Translational Science
Risankizumab is a high‐affinity neutralizing anti‐interleukin (IL)‐23 monoclonal antibody marketed in over 40 countries across the globe to treat several inflammatory diseases, such as plaque psoriasis (PsO), psoriatic arthritis (PsA), and Crohn's ...
Yinuo Pang, Ronilda D'Cunha, Insa Winzenborg, Geertruida Veldman, Valerie Pivorunas, Kori Wallace   +5 more
doaj   +2 more sources

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial [PDF]

Rheumatology and Therapy
Introduction Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who previously had inadequate ...
Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M. Soliman, Michael M. Chen, Byron Padilla, Alan Kivitz   +13 more
doaj   +2 more sources

Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children

Dermatology and Therapy, 2023
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease that affects men and women of all ages, including children. PRP is characterized by follicular and palmoplantar hyperkeratosis and salmon-colored scaling plaques.
Marta Kołt-Kamińska, Antonina Osińska, Ewa Kaznowska, Adam Reich   +3 more
doaj   +2 more sources

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date [PDF]

Psoriasis: Targets and Therapy, 2018
Álvaro Machado,1 Tiago Torres1,2 1Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal; 2Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal Abstract: Psoriasis is
Machado Á, Torres T
doaj   +3 more sources

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis

Drug Design, Development and Therapy, 2018
Isabel M Haugh,1 Allie K Preston,2 Dario N Kivelevitch,1 Alan M Menter1 1Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA; 2Texas A&M Health Science Center College of Medicine, Bryan, TX, USA Abstract: Risankizumab, a ...
Haugh IM, Preston AK, Kivelevitch DN, Menter AM   +3 more
doaj   +1 more source

Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy [PDF]

Dermatology Practical & Conceptual
Introduction: Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis. Objective: We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two ...
Federico Pirro, Giacomo Caldarola, Nicoletta Bernardini, Maria Grazia Celeste, Annunziata Dattola, Eleonora De Luca, Marco Galluzzo, Domenico Giordano, Chiara Izzi, Giulia Maretti , Lorenzo Marcelli, Roberto Ravasio, Antonio Giovanni Richetta, Nevena Skroza, Marina Talamonti, Arianna Zangrilli, Luca Bianchi, Giovanni Pellacani, Severino Persechino, Concetta Potenza, Ketty Peris, Clara De Simone   +21 more
doaj   +2 more sources

Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn’s Disease [PDF]

Gastro Hep Advances
Background and Aims: In phase 3 induction (ADVANCE and MOTIVATE) and maintenance (FORTIFY) trials, risankizumab was shown to benefit symptom and endoscopic defined outcomes in patients with Crohn’s disease (CD). We examined the effects of risankizumab on
Brian G. Feagan, Remo Panaccione, Stefan Schreiber, Edward V. Loftus, Jr., Laurent Peyrin-Biroulet, Takehiro Arai, Wan-Ju Lee, Jenny Griffith, Jasmina Kalabic, Kristina Kligys, Si Xuan, Xiaomei Liao, Marc Ferrante   +12 more
doaj   +2 more sources

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial

Rheumatology and Therapy
Introduction Patients with psoriatic arthritis (PsA) require treatment providing durable long-term efficacy in different disease domains as well as safety.
Lars Erik Kristensen, Mauro Keiserman, Kim Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M. Soliman, Michael Chen, Byron Padilla, Frank Behrens   +12 more
doaj   +2 more sources

Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials

Dermatology and Therapy
Introduction The presence (vs absence) of enthesitis/dactylitis is associated with greater psoriatic arthritis (PsA) activity and reduced health-related quality of life. Risankizumab, an interleukin 23 antagonist, demonstrated superior treatment efficacy
Shawn G. Kwatra, Saakshi Khattri, Ahmad Z. Amin, Roberto Ranza, Blair Kaplan, Linyu Shi, Byron Padilla, Ahmed M. Soliman, Dennis McGonagle   +8 more
doaj   +2 more sources